Yi Lin

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Juno/BMS
    Topic:
    Consulting
    Date added:
    07/20/2023
    Date updated:
    07/20/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    BlueBird Bio
    Topic:
    Consulting
    Date added:
    07/20/2023
    Date updated:
    07/20/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Janssen
    Topic:
    Consulting
    Date added:
    07/20/2023
    Date updated:
    07/20/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Legend BioTech
    Topic:
    Consulting
    Date added:
    07/20/2023
    Date updated:
    07/20/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Gamida Cells
    Topic:
    Consulting
    Date added:
    07/20/2023
    Date updated:
    07/20/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Novartis
    Topic:
    Consulting
    Date added:
    07/20/2023
    Date updated:
    07/20/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Iovance
    Topic:
    Consulting
    Date added:
    07/20/2023
    Date updated:
    07/20/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Takeda
    Topic:
    Consulting
    Date added:
    07/20/2023
    Date updated:
    07/20/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Fosun Kite
    Topic:
    Consulting
    Date added:
    07/20/2023
    Date updated:
    07/20/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Pfizer
    Topic:
    Consulting, Data Review Committee, DSMC
    Date added:
    07/20/2023
    Date updated:
    07/20/2023

Pages

Return to Seattle Cellular Therapy Summit: Patient-Centered Approach to Improve Outcomes